Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer

Cancer Treatment Reports

Volumn 62, Issue 7, 1978, Pages 1093-1095

  Hahn, R G ^a   Temkin, N R ^a   Savlov, E D ^a   Perlia, C ^b   Wampler, G L ^b   Horton, J ^b   Marsh, J ^b   Carbone, P P ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; SEMUSTINE; VINBLASTINE; VINBLASTINE SULFATE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG THERAPY; GALLBLADDER; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; NERVOUS SYSTEM; NEUROTOXICITY; PANCYTOPENIA; THERAPY; THROMBOCYTOPENIA; VOMITING;

BIOLOGY; CANCER; CLINIC ACTIVITIES; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--THERAPEUTIC USE; CONTRACEPTIVE AGENTS, PROGESTIN--THERAPEUTIC USE; CONTRACEPTIVE AGENTS--THERAPEUTIC USE; DISEASES; FAMILY PLANNING; MEDROXYPROGESTERONE ACETATE--THERAPEUTIC USE; NEOPLASMS; PHYSIOLOGY; PROSPECTIVE STUDIES; RENAL EFFECTS; RESEARCH METHODOLOGY; STUDIES; TREATMENT; UROGENITAL EFFECTS; UROGENITAL SYSTEM;

ADENOCARCINOMA; CLINICAL TRIALS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY NEOPLASMS; MEDROXYPROGESTERONE; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; PROGNOSIS; SEMUSTINE; VINBLASTINE;

EID: 0018103243     PISSN: 03615960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)